Laila Staerk1, Emil Loldrup Fosbøl2,3, Gregory Y H Lip4, Morten Lamberts1,2, Anders Nissen Bonde1, Christian Torp-Pedersen5, Brice Ozenne6, Thomas Alexander Gerds6, Gunnar Hilmar Gislason1,3,7,8, Jonas Bjerring Olesen1,9. 1. Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark. 2. Department of Cardiology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen Ø, Denmark. 3. The Danish Heart Foundation, 1127 Copenhagen K, Denmark. 4. University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK. 5. Department of Cardiology and Clinical Epidemiology, Aalborg University Hospital and Department of Health, Science and Technology, Aalborg University, 9000 Aalborg, Denmark. 6. Section of Biostatistics, Department of Public Health, University of Copenhagen, 1014 Copenhagen K, Denmark. 7. Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark. 8. The National Institute of Public Health, University of Southern Denmark, 1353 Copenhagen K, Denmark. 9. Department of Cardiology, Copenhagen University Hospital Hillerød, 3400 Hillerød, Denmark.
Abstract
BACKGROUND: Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse. PURPOSE: To compare dabigatran, rivaroxaban, and apixaban vs. VKA and the risk of stroke/thromboembolism (TE) and intracranial bleeding in AF. METHODS: Using Danish nationwide registries (2011-15), anticoagulant-naïve AF patients were identified when initiating VKA or an NOAC. Outcomes were stroke/TE and intracranial bleeding. Multiple outcome-specific Cox regression was performed to calculate average treatment effects as standardized differences in 1-year absolute risks. RESULTS: Overall, 43 299 AF patients initiated VKA (42%), dabigatran (29%), rivaroxaban (13%), and apixaban (16%). Mean CHA2DS2-VASc (SD) score was: VKA 2.9 (1.6), dabigatran 2.7 (1.6), rivaroxaban 3.0 (1.6), and apixaban 3.1 (1.6). Within patient-specific follow-up limited to the first 2 years, 1054 stroke/TE occurred and 261 intracranial bleedings. Standardized absolute risk (95% CI) of stroke/TE at 1 year after initiation of VKA was 2.01% (1.80% to 2.21%). In relation to VKA, the absolute risk differences were for dabigatran 0.11% (-0.16% to 0.42%), rivaroxaban 0.05% (-0.33% to 0.48%), and apixaban 0.45% (-0.001% to 0.93%). For the intracranial bleeding outcome, the standardized absolute risk at 1 year was for VKA 0.60% (0.49% to 0.72%); the corresponding absolute risk differences were for dabigatran -0.34% (-0.47% to - 0.21%), rivaroxaban -0.13% (-0.33% to 0.08%), and apixaban -0.20% (-0.38% to - 0.01%). CONCLUSIONS: Among anticoagulant-naïve AF patients, treatment with NOACs was not associated with significantly lower risk of stroke/TE compared with VKA, but intracranial bleeding risk was significantly lower with dabigatran and apixaban. Published on behalf of the European Society of Cardiology. All rights reserved.
BACKGROUND: Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse. PURPOSE: To compare dabigatran, rivaroxaban, and apixaban vs. VKA and the risk of stroke/thromboembolism (TE) and intracranial bleeding in AF. METHODS: Using Danish nationwide registries (2011-15), anticoagulant-naïve AF patients were identified when initiating VKA or an NOAC. Outcomes were stroke/TE and intracranial bleeding. Multiple outcome-specific Cox regression was performed to calculate average treatment effects as standardized differences in 1-year absolute risks. RESULTS: Overall, 43 299 AF patients initiated VKA (42%), dabigatran (29%), rivaroxaban (13%), and apixaban (16%). Mean CHA2DS2-VASc (SD) score was: VKA 2.9 (1.6), dabigatran 2.7 (1.6), rivaroxaban 3.0 (1.6), and apixaban 3.1 (1.6). Within patient-specific follow-up limited to the first 2 years, 1054 stroke/TE occurred and 261 intracranial bleedings. Standardized absolute risk (95% CI) of stroke/TE at 1 year after initiation of VKA was 2.01% (1.80% to 2.21%). In relation to VKA, the absolute risk differences were for dabigatran 0.11% (-0.16% to 0.42%), rivaroxaban 0.05% (-0.33% to 0.48%), and apixaban 0.45% (-0.001% to 0.93%). For the intracranial bleeding outcome, the standardized absolute risk at 1 year was for VKA 0.60% (0.49% to 0.72%); the corresponding absolute risk differences were for dabigatran -0.34% (-0.47% to - 0.21%), rivaroxaban -0.13% (-0.33% to 0.08%), and apixaban -0.20% (-0.38% to - 0.01%). CONCLUSIONS: Among anticoagulant-naïve AF patients, treatment with NOACs was not associated with significantly lower risk of stroke/TE compared with VKA, but intracranial bleeding risk was significantly lower with dabigatran and apixaban. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Alejandro Isidoro Pérez Cabeza; Rafael Bravo Marques; Pedro Antonio Chinchurreta Capote; Francisco Ruiz Mateas; Christina L Fanola; Gabriel Rosas Cervantes; Jose Antonio González Correa; Almudena Valle Alberca; Fidel Mesa Prado; Sergio López Tejero; Christian Thomas Ruff Journal: Clin Cardiol Date: 2018-08-20 Impact factor: 2.882
Authors: Benjamin J R Buckley; Deirdre A Lane; Peter Calvert; Juqian Zhang; David Gent; C Daniel Mullins; Paul Dorian; Shun Kohsaka; Stefan H Hohnloser; Gregory Y H Lip Journal: J Clin Med Date: 2022-06-30 Impact factor: 4.964
Authors: Mariam Ujeyl; Ingrid Köster; Hans Wille; Thomas Stammschulte; Rebecca Hein; Sebastian Harder; Ursula Gundert-Remy; Julian Bleek; Peter Ihle; Helmut Schröder; Gerhard Schillinger; Anette Zawinell; Ingrid Schubert Journal: Eur J Clin Pharmacol Date: 2018-06-16 Impact factor: 2.953
Authors: Patrick Blin; Caroline Dureau-Pournin; Jacques Bénichou; Yves Cottin; Patrick Mismetti; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Nicholas Moore Journal: Am J Cardiovasc Drugs Date: 2020-02 Impact factor: 3.571
Authors: Xiaoyan Li; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip; Steve Deitelzweig Journal: PLoS One Date: 2018-01-26 Impact factor: 3.240